Nacuity Pharmaceuticals develops targeted therapies to halt oxidative tissue damage, which contributes to retinitis pigmentosa and other serious chronic conditions. Their clinical programs focus on addressing the underlying mechanisms of oxidative stress in blinding eye diseases, including cataract and cystinosis.
Funding
$27.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oxidative tissue damage contributes to the progression of retinitis pigmentosa, cataract, cystinosis, and other serious chronic conditions, potentially leading to vision loss and other complications. Current treatments often fail to address the underlying mechanisms of oxidative stress effectively.
Solution
Nacuity Pharmaceuticals develops targeted prescription therapies designed to halt oxidative tissue damage, a key driver in blinding eye diseases and a range of chronic conditions. Their approach focuses on addressing the root causes of oxidative stress to prevent or slow disease progression. Nacuity's clinical programs are advancing differentiated treatments for retinitis pigmentosa, cataract, and cystinosis. These therapies aim to provide more effective solutions for patients suffering from these conditions.
Target Audience
The primary target audience includes individuals suffering from retinitis pigmentosa, cataract, cystinosis, and other conditions characterized by oxidative stress, as well as the ophthalmologists and other healthcare providers who treat them.
Features
- Targeted therapies designed to interrupt the cycle of oxidative tissue damage.
- Clinical programs focused on retinitis pigmentosa, cataract, and cystinosis.
- Development of prescription therapies.